APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rufinamide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rufinamide Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchRufinamide Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Rufinamide Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal Rufinamide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rufinamide Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Rufinamide Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Rufinamide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rufinamide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rufinamide market include Eisai, Mylan, Glenmark Pharms and West-ward Pharms, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Rufinamide market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rufinamide and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rufinamide revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rufinamide market.

Rufinamide Segment by Company

Eisai

Mylan

Glenmark Pharms

West-ward Pharms

Rufinamide Segment by Type

Tablets

Oral suspension

Rufinamide Segment by Application

Adults

Pediatric patients

Rufinamide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rufinamide status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Rufinamide key companies, revenue, market share, and recent developments.

3. To split the Rufinamide breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Rufinamide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rufinamide significant trends, drivers, influence factors in global and regions.

6. To analyze Rufinamide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rufinamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rufinamide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rufinamide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rufinamide industry.

Chapter 3: Detailed analysis of Rufinamide company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Rufinamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Rufinamide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rufinamide Industry Trends Table 2. Rufinamide Industry Drivers Table 3. Rufinamide Industry Opportunities and Challenges Table 4. Rufinamide Industry Restraints Table 5. Global Rufinamide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rufinamide Revenue Share by Company (2021-2026) Table 7. Global Rufinamide Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Rufinamide Key Company Manufacturing Base & Headquarters Table 9. Global Rufinamide Company, Product Type & Application Table 10. Global Rufinamide Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Rufinamide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablets Table 15. Significant Companies of Oral suspension Table 16. Global Rufinamide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Rufinamide Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Rufinamide Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Rufinamide Sales Value Share by Type (2021-2026) Table 20. Global Rufinamide Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Adults Table 22. Significant Companies of Pediatric patients Table 23. Global Rufinamide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Rufinamide Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Rufinamide Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Rufinamide Sales Value Share by Application (2021-2026) Table 27. Global Rufinamide Sales Value Share by Application (2027-2032) Table 28. Global Rufinamide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Rufinamide Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Rufinamide Sales Value Share by Region (2021-2026) Table 31. Global Rufinamide Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Rufinamide Sales Value Share by Region (2027-2032) Table 33. Global Rufinamide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Rufinamide Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Rufinamide Sales Value Market Share by Country (2021-2026) Table 36. Global Rufinamide Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Rufinamide Sales Value Market Share by Country (2027-2032) Table 38. Eisai Company Information Table 39. Eisai Business Overview Table 40. Eisai Rufinamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Eisai Rufinamide Product Portfolio Table 42. Eisai Recent Development Table 43. Mylan Company Information Table 44. Mylan Business Overview Table 45. Mylan Rufinamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Mylan Rufinamide Product Portfolio Table 47. Mylan Recent Development Table 48. Glenmark Pharms Company Information Table 49. Glenmark Pharms Business Overview Table 50. Glenmark Pharms Rufinamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Glenmark Pharms Rufinamide Product Portfolio Table 52. Glenmark Pharms Recent Development Table 53. West-ward Pharms Company Information Table 54. West-ward Pharms Business Overview Table 55. West-ward Pharms Rufinamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. West-ward Pharms Rufinamide Product Portfolio Table 57. West-ward Pharms Recent Development Table 58. Research Programs/Design for This Report Table 59. Authors List of This Report Table 60. Secondary Sources Table 61. Primary Sources List of Figures Figure 1. Rufinamide Product Image Figure 2. Global Rufinamide Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rufinamide Market Size (2021-2032) & (US$ Million) Figure 4. Global Rufinamide Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablets Image Figure 8. Oral suspension Image Figure 9. Global Rufinamide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Rufinamide Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Rufinamide Sales Value Share by Type (2021-2032) Figure 12. Adults Image Figure 13. Pediatric patients Image Figure 14. Global Rufinamide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Rufinamide Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Rufinamide Sales Value Share by Application (2021-2032) Figure 17. Global Rufinamide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Rufinamide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Rufinamide Sales Value (2021-2032) & (US$ Million) Figure 20. North America Rufinamide Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Rufinamide Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Rufinamide Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Rufinamide Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Rufinamide Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Rufinamide Sales Value (2021-2032) & (US$ Million) Figure 26. South America Rufinamide Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Rufinamide Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Rufinamide Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Rufinamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Rufinamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Rufinamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Oral suspension
Applications
  • Adults
  • Pediatric patients
Companies covered
  • Eisai
  • Mylan
  • Glenmark Pharms
  • West-ward Pharms

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rufinamide Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rufinamide Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Rufinamide Market Dynamics
  1. 2.1 Rufinamide Industry Trends
  2. 2.2 Rufinamide Industry Drivers
  3. 2.3 Rufinamide Industry Opportunities and Challenges
  4. 2.4 Rufinamide Industry Restraints
3 Rufinamide Market by Company
  1. 3.1 Global Rufinamide Company Revenue Ranking in 2025
  2. 3.2 Global Rufinamide Revenue by Company (2021-2026)
  3. 3.3 Global Rufinamide Company Ranking (2024-2026)
  4. 3.4 Global Rufinamide Company Manufacturing Base and Headquarters
  5. 3.5 Global Rufinamide Company Product Type and Application
  6. 3.6 Global Rufinamide Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Rufinamide Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Rufinamide Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Rufinamide Market by Type
  1. 4.1 Rufinamide Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Oral suspension
  4. 4.2 Global Rufinamide Sales Value by Type
  5. 4.2.1 Global Rufinamide Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Rufinamide Sales Value by Type (2021-2032)
  7. 4.2.3 Global Rufinamide Sales Value Share by Type (2021-2032)
5 Rufinamide Market by Application
  1. 5.1 Rufinamide Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Pediatric patients
  4. 5.2 Global Rufinamide Sales Value by Application
  5. 5.2.1 Global Rufinamide Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Rufinamide Sales Value by Application (2021-2032)
  7. 5.2.3 Global Rufinamide Sales Value Share by Application (2021-2032)
6 Rufinamide Regional Value Analysis
  1. 6.1 Global Rufinamide Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rufinamide Sales Value by Region (2021-2032)
  3. 6.2.1 Global Rufinamide Sales Value by Region: 2021-2026
  4. 6.2.2 Global Rufinamide Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rufinamide Sales Value (2021-2032)
  7. 6.3.2 North America Rufinamide Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Rufinamide Sales Value (2021-2032)
  10. 6.4.2 Europe Rufinamide Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Rufinamide Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Rufinamide Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Rufinamide Sales Value (2021-2032)
  16. 6.6.2 South America Rufinamide Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Rufinamide Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Rufinamide Sales Value Share by Country, 2025 VS 2032
7 Rufinamide Country-level Value Analysis
  1. 7.1 Global Rufinamide Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rufinamide Sales Value by Country (2021-2032)
  3. 7.2.1 Global Rufinamide Sales Value by Country (2021-2026)
  4. 7.2.2 Global Rufinamide Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Rufinamide Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Rufinamide Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Rufinamide Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Rufinamide Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Rufinamide Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Rufinamide Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Rufinamide Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Rufinamide Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Rufinamide Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Rufinamide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Rufinamide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Rufinamide Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Rufinamide Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Rufinamide Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Rufinamide Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Rufinamide Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Rufinamide Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Rufinamide Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Rufinamide Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Rufinamide Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Rufinamide Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Rufinamide Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Rufinamide Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Rufinamide Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Rufinamide Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Rufinamide Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Rufinamide Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Rufinamide Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Rufinamide Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Rufinamide Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Rufinamide Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Rufinamide Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Rufinamide Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Rufinamide Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Rufinamide Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Rufinamide Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Rufinamide Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Rufinamide Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Rufinamide Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Rufinamide Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Rufinamide Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Rufinamide Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Rufinamide Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Rufinamide Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Rufinamide Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Rufinamide Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Rufinamide Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Rufinamide Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Rufinamide Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Rufinamide Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Rufinamide Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Rufinamide Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Rufinamide Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Rufinamide Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Rufinamide Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Rufinamide Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Rufinamide Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Rufinamide Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Rufinamide Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Rufinamide Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Rufinamide Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Rufinamide Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Rufinamide Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Rufinamide Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Rufinamide Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Rufinamide Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Rufinamide Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Rufinamide Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Rufinamide Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Rufinamide Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Rufinamide Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Rufinamide Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Rufinamide Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Rufinamide Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Rufinamide Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Rufinamide Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Rufinamide Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Rufinamide Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Rufinamide Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Rufinamide Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Rufinamide Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Rufinamide Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Rufinamide Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Rufinamide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Rufinamide Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Rufinamide Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Rufinamide Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Rufinamide Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 Glenmark Pharms
  14. 8.3.1 Glenmark Pharms Company Information
  15. 8.3.2 Glenmark Pharms Business Overview
  16. 8.3.3 Glenmark Pharms Rufinamide Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Glenmark Pharms Rufinamide Product Portfolio
  18. 8.3.5 Glenmark Pharms Recent Developments
  19. 8.4 West-ward Pharms
  20. 8.4.1 West-ward Pharms Company Information
  21. 8.4.2 West-ward Pharms Business Overview
  22. 8.4.3 West-ward Pharms Rufinamide Revenue and Gross Margin (2021-2026)
  23. 8.4.4 West-ward Pharms Rufinamide Product Portfolio
  24. 8.4.5 West-ward Pharms Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst